ContraFect Corporation ContraFect Corporation Nasdaq: CFRX

Navigate ContraFect Corporation

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Lysins
    • Amurins
    • Publications / Posters
    • Video Library
  • Pipeline
    • Overview
    • Exebacase
    • CF-370
    • Gram-negative Lysins
    • Amurins
  • Investors & Media
    • Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Analyst Coverage
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Press Releases

Investors & Media

  • Home
  • Investors & Media
  • News / Events
  • Press Releases
Investors & Media

Investors & Media

  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • Events
    • Email Alerts
  • Presentations
  • Company Information
  • Financial Information
  • Analyst Coverage
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

ContraFect to Present at Biotech Showcase 2019

December 20, 2018

ContraFect to Present at Piper Jaffray Health Care Conference

November 19, 2018

ContraFect Appoints Michael Messinger as Chief Financial Officer

November 12, 2018

ContraFect Announces Third Quarter 2018 Financial Results

November 8, 2018

ContraFect to Present at 2nd International Symposium on Antimicrobial Hydrolytic Enzymes

November 1, 2018

ContraFect to Participate in World Antimicrobial Resistance Congress 2018

October 22, 2018

ContraFect to Present at the “Exploring the Antibiotic Pipeline 2018” Symposium and also to Present New Data on CF-301 (exebacase) at IDWeek 2018

September 25, 2018

ContraFect to Present at Two Upcoming Investor Conferences

September 20, 2018

ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia

September 6, 2018

ContraFect to Present at Two Upcoming Investor Conferences

August 29, 2018

RSS
  • 1
  • 2
  • 3
  • Next »
© 2023 ContraFect Corporation. All Rights Reserved.
Copyright Privacy Policy Expanded Access Policy Disclaimer Site Map
LinkedIn Twitter